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Objective: To investigate the role of survivin in osteosarcoma metastasis.
Methods: Small interfering RNA (siRNA) was used to knockdown the expression of
survivin and a5 integrin in the human osteosarcoma cell line MG63. Western blotting and
immunostaining methods were used to assessed the effect of survivin knockdown on the
expression of a5 integrin through ﬂow cytometry and ﬂuorescence microscopy detection.
Meanwhile, the invasion and migration of transfected cells in Transwell and wound
healing assays were probed, and the growth situation of these cells transplanted into nude
mice was monitored.
Results: Knockdown of survivin expression could inhibit the invasion and migration of
osteosarcoma MG64 cells in vitro and the expression of a5 integrin on osteosarcoma
MG64 cell surface, suggesting that survivin can inhibit the invasion and migration of
osteosarcoma cells through downregulation of a5 integrin. Anti-a5 integrin antibody
could also markedly decrease the capability of invasion and migration of osteosarcoma
MG64 cells. Additionally, knockdown of survivin expression could slow the growth of
osteosarcoma MG63 cells transplanted into nude mice.
Conclusions: Survivin-directed anti-tumor strategies might be an effective method in the
treatment of osteosarcoma.1. Introduction
Osteosarcoma, the most frequently-encountered primary
malignant tumor of bones, represents over 56% of all bone tu-
mors, and it is the third most frequent cause of cancer in ado-
lescents [1–3]. Conventional treatments for osteosarcoma include
surgical resection, chemotherapy and radiotherapy, but the
prognosis remains poor due to aggressive inﬁltration into localtissue and extremely-high metastatic rate [4]. Hence, novel
therapeutic approaches, such as biological therapies against
speciﬁc targets, are urgently sought [5].
Survivin is an inhibitor of apoptosis and has been reported to
confer tumor resistance to apoptotic stimuli [6]. It is abundantly
expressed during fetal development, but its expression is low in
most adult human tissues [7]. In some tumor cells, survivin
expression increases aberrantly, which makes it be an
attractive anti-tumor target. Elevated survivin expression is
associated with enhanced proliferation, reduced apoptosis,
resistance to chemotherapy and increased tumor recurrence [8,9].
In an animal model, survivin has been reported to contribute to
tumor metastasis [10]. The level of survivin expression was
correlated with malignant degree of osteosarcoma [11], even
could be a prognostic indicator for osteosarcoma [12–14].
However, little is known regarding the speciﬁc role of survivin
in osteosarcoma. Inhibition of survivin was previously
reported to reduce proliferation and increase apoptosis of theY-NC-ND license (http://
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also associated with spontaneous pulmonary metastasis of
osteosarcoma in a mouse model. Nevertheless, the precise
mechanisms that survivin regulates tumor cell metastasis are
poorly understood.
McKenzie et al. [17] found that in melanoma, survivin could
promote the proliferation of tumor cells via enhancement of
integrin expression. The integrin family can not only act as
receptors for cell adhesion molecules, but also can mediate
cell proliferation, differentiation, apoptosis and motility [18–24].
These cell–cell interactions are crucial for tumor cell motility
and growth [20]. Integrin expression is associated with
metastatic phenotype of various tumors including
osteosarcoma [18–21]. Blocking the expression of integrins with
speciﬁc antibodies can decrease the invasiveness of tumor
cells in vitro and in vivo [25].
In this study, the expression of survivin in the human os-
teosarcoma cell line MG63 was knocked down, and its effect
on the properties of these cells important for metastasis was
investigated. It was found that knockdown of survivin
expression could inhibit MG63 invasion and migration, and
downregulate the expression of a5 integrin. Subsequently, it
was observed that decreased expression of a5 integrin
mimicked the effect of survivin knockdown on MG63 invasion
and migration. The study further conﬁrmed that the growth of
osteosarcoma MG63 cells transplanted into nude mice was
suppressed obviously. All these ﬁndings suggest that survivin
may promote osteosarcoma metastasis by means of expression
of a5 integrin.2. Materials and methods
2.1. Cell culture
Human osteosarcoma cell line MG63 cells (ATCC, Mana-
ssas, VA, USA) were cultured and incubated in DMEM con-
taining 10% FBS at 37 C.2.2. Transwell migration and invasion assays
The migratory response of MG63 cells was measured by
Transwell migration assay. Speciﬁc operations [26] were as
follows: The experiment was performed using a Transwell
cell culture plate (Corning Costar, Rochester, NY, USA).
The Transwell inserts (8 mm pore size) were pre-coated with
Matrigel (Becton Dickinson, Bedford, MA). The upper
chamber contained the cells in culture medium (5 × 105/mL)
with 1% FBS, and the lower chamber contained culture me-
dium with 20% FBS. The cells transfected with survivin-
siRNA (si-survivin) or scramble RNA were cultured in trans-
well inserts for 48 h. Non-migrated cells were scraped from the
upper surface of the membrane with a cotton swab, and
migrated cells on the underside of the ﬁlters were ﬁxed in
methanol for 15 min and stained with 0.05% crystal violet in
PBS for 15 min. The number of cells was counted under a
microscope.
2.3. Wound healing assay
MG63 cells were cultured as conﬂuent monolayers and
wounded by scratching with a sterile pipette tip. Woundedmonolayers were washed twice with PBS to remove detached
cells and incubated in fresh medium for an additional 48 h.
Images of the wounds were taken immediately at 0 h and
48 h. Migration of cells into the wound was recorded using a
phase contrast microscope. The mean percentage of remaining
cell-free area was quantiﬁed using ImageJ software, and
compared with the area of initial wound to indicate wound
healing.2.4. Flow cytometry
MG63 cells were seeded in 6-well plates at 5 × 104 cells per well
and transfected with siRNAs (sense: 50-CAGACUUGGCCCA-
GUGUUU-30, antisense: 50-AAACACUGGGCCAAGUCUG-30)
obtained from Shanghai GeneChem Co. Ltd (China). After 24 h,
the cells were harvested using 0.05% trypsin solution (Sigma, St.
Louis, MO, USA), ﬁxed in 70% ethanol, washed and stained with
anti-human a5 integrin mAb (1: 2 000, ebioscience, San Diego,
CA, USA), prior to analysis using a FACSort ﬂow cytometer (BD,
NJ, USA).
2.5. Western blotting analysis
The cells transfected with si-survivin were harvested after
two days and cell lysates were loaded onto a 4%–12% Bis-Tris
gel, electrophoresed and transferred to a polyvinylidenedi-
ﬂuoride membrane. The membrane was subsequently immu-
noblotted with rabbit polyclonal anti-survivin (Novus)
followed by horseradish peroxidase-conjugated goat anti-
rabbit IgG (Pierce). The signals were visualized using an
enhanced ECL kit from Amersham Pharmacia Biotech.2.6. Immunoﬂuorescence
Transfected cells were washed, ﬁxed with methanol, and air-
dried, then incubated with rabbit polyclonal anti-survivin anti-
body (Novus Biologicals) and secondary ﬂuorescent antibody.
The slides were washed and mounted with 40,6-diamidino-2-
phenylindole. Images were captured by Zeiss Axioplan 2 im-
aging microscope.2.7. Xenograft tumor formation
Six-week-old nude mice (Shanghai SLAC Laboratory
Animal Co. Ltd, China) were bred and maintained under
speciﬁc pathogen-free conditions in accordance with the
Shanghai Medical Experimental Animal Care Commission.
MG63 cells (5 × 106) transfected with either the scramble
RNA or si-survivin were inoculated into the left and right
ﬂanks of nude mice, respectively. Three weeks after
inoculation, the mice were sacriﬁced and the tumors were
weighed.
2.8. Statistical analysis
Statistical analysis was performed using SPSS 19.0
software (SPSS, Chicago, IL, USA). Data were expressed as the
mean ± SD of at least three independent experiments. Statistical
signiﬁcance was analyzed using a Student's t-test (two-tailed).
P < 0.05 was considered to be statistically signiﬁcant.
Figure 1. Knockdown of survivin expression in MG63 cells by siRNA and its role in cell invasion.
(A) Western blotting assay. Tubulin expression was used as a loading control. Src: Scramble RNA. (B) Transwell assay was employed to evaluate
the invasion of these cells. The quantitative results for each group are shown as the number of invaded cells 24 h after incubation. (C) Wound
healing assay. The quantitative results for each group are shown as the fold change of migrated cells vs. scramble control 48 h after incubation.
**P < 0.01.
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3.1. Survivin was required for human osteosarcoma
MG63 cell migration
After transfection with siRNA, the level of survivin in
MG63 cells was detected ﬁrst. As shown in Figure 1A, the
content of survivin in the cells transfected with si-survivin was
signiﬁcantly lower than that in the cells transfected with
scramble RNA, indicating successful knockdown of survivin
expression.
The effect of survivin on invasiveness of MG63 cells was
evaluated by Transwell assay. The percentage of survivin
knockdown cells that migrated was signiﬁcantly lower than
that of cells transfected with scramble RNA (Figure 1B). The
effect of survivin on MG63 cell migration was further assessed
by wound healing assay. It was found that survivin knockdown
profoundly inhibited the MG63 cell migration (Figure 1C).
Collectively, these results demonstrate that survivin is required
for human osteosarcoma MG63 cell motility and its knock-
down greatly attenuate MG63 cell migration, suggesting that
survivin might be involved in the process of osteosarcoma
metastasis.Figure 2. Knockdown of survivin expression led to deceased expression of
a5 integrin.
(A) Flow cytometry. (B) Fluorescent microscopy.3.2. Knockdown of survivin expression led to down-
regulation of a5 integrin in MG63 cells
Considering the possibility that knockdown of survivin
expression in MG63 cells might reﬂect decreased cell adhesion to
extracellular matrix, it was concluded that a5 integrin might be
Figure 3. Downregulation of a5 integrin contributed to MG63 cell metastasis.
(A) Flow cytometry. (B) Fluorescent microscopy. (C) Transwell assay. (D) Wound healing assay. **P < 0.01.
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that the expression of a5 integrin was markedly reduced in si-
survivin transfected cells using ﬂow cytometry (Figure 2A) and
ﬂuorescent microscopy (Figure 2B), suggesting that survivin is
likely an upstream regulator of a5 integrin.
3.3. Knockdown of a5 integrin resulted in decreased
metastatic ability of MG63 cells
MG63 cells with a5 integrin targeting siRNA were
transduced. The knockdown of a5 integrin expression on the
cell surface was conﬁrmed by ﬂow cytometry (Figure 3A),
ﬂuorescent microscopy (Figure 3B) and immunostaining
assay.
Transwell and wound healing assays were conducted
repeatedly in MG63 cells with knockdown of a5 integrin. As
shown in Figure 3C, the cell invasiveness was signiﬁcantlyweakened after knockdown of a5 integrin. Additionally,
wound healing assay revealed that the migration of cells was
over two fold in a5 integrin knockdown cells than scramble
RNA transfected cells (Figure 3D). These results indicate that
a5 integrin is related to the migration of human osteosarcoma
cells.
3.4. Anti-a5 integrin antibody could effectively reduce
MG63 motility
The invasiveness and migration of MG63 cells in Transwell
and wound healing assays were measured under the action of
anti-a5 integrin antibody (M200). It was found that the inva-
siveness and migration of tumor cells could be inhibited in the
treatment of MG63 tumor cells using a5 integrin (Figure 4),
suggesting that anti-a5 integrin can effectively block the
metastasis of MG63 cells.
Figure 5. Tumorigenicity of scramble RNA and si-survivin cells (1 × 106)
after subcutaneous injection in the ﬂanks of nude mice (n = 10).
(A) One representative mouse and formed tumors are shown. (B) The
quantiﬁcation of tumor weight is shown on the bottom (n = 10)
(**P < 0.01).
Figure 4. Anti-a5 integrin antibody decreased migration and invasiveness of MG63 cells.
(A) Transwell assay. (B) Wound healing assay. *P < 0.05.
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tumor growth in vivo
As shown in Figure 5, the tumor volume of survivin
knockdown was smaller than that of cells transduced with
scramble RNA. These results suggest that inhibition of survivin
expression may suppress xenograft tumor formation in osteo-
sarcoma cells in vivo.
4. Discussion
Survivin can protect osteosarcoma cells from apoptosis and
enhance proliferation in vitro [15,16], but its role in osteosarcoma
is not well understood. In this study, the role of survivin in the
human osteosarcoma metastasis was explored, and siRNA
knockdown of survivin expression was established in the
human osteosarcoma cell line. It was found that knockdown of
survivin expression could reduce the invasion and migration
of this human osteosarcoma cell line in vitro, suggesting that
survivin may be required for the metastasis of human
osteosarcoma.
a5 integrin is a sort of protein that can make cells adhere to
the extracellular matrix. The results in this study displayed that
knockdown of survivin expression could decrease the expression
of a5 integrin on the cell surface. On the contrary, knockdown
of a5 integrin could also reduce the invasion and migration of
this human osteosarcoma cell line, suggesting that knockdown
of survivin expression may decrease the metastasis via inhibition
of a5 integrin expression, thus reducing the capability of tumor
cells adhering to the extracellular matrix.
In this study, a mouse model of osteosarcoma was estab-
lished by transplantation of the human osteosarcoma cell line
into nude mice so as to probe the role of survivin in osteosar-
coma metastasis in vivo. It was found that knockdown of sur-
vivin expression could slow the tumor growth of the
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vivin may involve in the process of osteosarcoma proliferation.
The results in this study also revealed that inhibition of
survivin was detrimental to human osteosarcoma cell lines,
which were consistent with the previous studies [15,16].
Upregulation of survivin-mediated a5 integrin could promote
the metastasis of melanoma [17]. It is reported that survivin is
associated with spontaneous pulmonary metastasis of
osteosarcoma in another mouse model [10]. All of these
ﬁndings point to a potential target for osteosarcoma. As
survivin and a5 integrin are required for osteosarcoma
metastasis, suppressing the expression of survivin or a5
integrin in tumor cells or blocking the activity of these
proteins may reduce the tumor metastasis. For instance,
survivin siRNA, antagonizing survivin function by dominant-
negative surviving and anti-a5 integrin antibody all are
conductive to the development of osteosarcoma treatment.
Additionally, it was also found in this study that blocking a5
integrin antibody in vitro could inhibit the invasion and migra-
tion of the human osteosarcoma cell line.
It still needs further studies about the role of survivin in tu-
mor cells and downstream signaling processes involved in
survivin-induced metastasis. Survivin is expressed in some adult
cells, but its inhibition is not associated with restrictive side
effects in animal models [7]. In recent years, a small molecule
inhibitor has been reported to inhibit the proliferation of
human osteosarcoma cells and induce its apoptosis in a
subcutaneous xenograft tumor model via downregulation of
survivin pathway [27]. Hence, studying the drugs targeting to
survivin may provide a new idea for osteosarcoma.
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